Meeting
2016 Gastrointestinal Cancers Symposium
An open label, randomized phase 3 trial evaluating the treatment (tx) effects of panitumumab (pmab) + best supportive care (BSC) versus BSC in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) and in WT RAS mCRC.
Authors
Tae Won Kim
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Tae Won Kim , Anneli Elme , Zvonko Kusic , Joon Oh Park , Anghel Adrian Udrea , Sun Young Kim , Joong Bae Ahn , Ricardo Villalobos Valencia , Krishnan Srinivasan , Ante Bilic , Nebojsa Manojlovic , Jun Dong , Xuesong Guan , Catherine Lofton-Day , A. Scott Jung , Eduard Vrdoljak
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01412957
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 642)
DOI
10.1200/jco.2016.34.4_suppl.642
Abstract #
642
Poster Bd #
H3
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Final results from a phase III trial evaluating panitumumab (pmab) + best supportive care (BSC) vs BSC in chemorefractory wild-type (WT) KRAS exon 2 and WT RAS metastatic colorectal cancer (mCRC).
First Author: Tae Won Kim
Poster
2017 ASCO Annual Meeting
Early tumor shrinkage (ETS) and depth of response (DpR) in wild-type (WT) RAS tumors from the phase III trial of panitumumab (pmab) plus best supportive care (BSC) versus BSC in chemorefractory metastatic colorectal cancer (mCRC).
First Author: Tae Won Kim
Poster
2017 Gastrointestinal Cancers Symposium
A phase Ib/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT): Biomarker substudy.
First Author: Amanda Rose Townsend
Poster
2016 Gastrointestinal Cancers Symposium
Outcomes by hypomagnesemia (hypomag) in the randomized phase III ASPECCT trial of patients (pts) with chemofractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC).
First Author: Marc Peeters